Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 5,949

Document Document Title
WO/2017/097085A1
Disclosed is a preparation method for a eutectic hydrate crystal form II of AHU-377 and diovan trisodium salt, comprising: firstly, obtaining a clear solution of an AHU-377 and diovan trisodium salt compound, a solvent of the clear solut...  
WO/2017/098038A1
The present invention relates to new class of functionalized macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Re...  
WO/2017/099530A1
Disclosed is a method of preparing an intermediate for an oxazolidinone derivative, which enables 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine to be produced at high yield and high purity, thus exhibiting high preparation efficiency und...  
WO/2017/096772A1
Disclosed is a method for preparing an anti-heart-failure medicine LCZ696. The preparing method comprises the following steps (formula (I)): in an organic solvent, a sacubitril dicyclohexylamine salt reacts with valsartan under the effec...  
WO/2017/098044A1
The present invention relates to new class of dimeric macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance...  
WO/2017/093351A1
The invention relates to the provision of novel inhibitors for the cytosolic phospholipases A2, the inhibitors having a special metabolization stability.  
WO/2017/093263A1
The present invention relates to a process for the synthesis of 3,6 functionalized 1,2,4,5-tetrazine compounds of formula (I); wherein A and B being the same; and wherein at least one of R1, R1', R2 and R2' and at least one of R10 and R1...  
WO/2017/091041A1
The present invention provides: a novel salt of Fimasartan having excellent solubility, bioavailability, and physicochemical properties; a method for preparing the same; and a pharmaceutical composition containing the same.  
WO/2017/080443A1
A class of compounds of monosulfonic phenyltetrazole, with the structure of 2- (R1 phenyl) -5 (2-sulfonic phenyl) -2H-tetrazole. The 2-sulfonic phenyl tetrazolium salt of this invention has advantages of low toxicity, short synthetic rou...  
WO/2017/082620A1
The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound containing the same, and a pharmaceutical composition containing the same as an active ingredient...  
WO/2017/080290A1
Provided a complex of formula is [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate- (S)-3'-methyl-2'- (pentanoyl {2''-(tetrazol-5-ylate) biphenyl-4'-ylmethyl}amino) butyrate] 6·XCa2+·YNa+·ZH2O, wherein ...  
WO/2017/001926A8
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the trea...  
WO/2017/055146A1
Described are acylated N-(1,2,5-oxadiazole-3-yl)-, N-(1,3,4-oxadiazole-2-yl)-, N-(tetrazole-5-yl)- and N-(triazole-5-yl)-aryl carboxamides of formula (I) and the use thereof as herbicides. In said formula (I), R, V, X, Y, and Z are group...  
WO/2017/059303A1
Provided herein are vinylogous thioester compounds and methods for using the compounds.  
WO/2017/053564A1
An especially robust compound and its derivative metal complexes that are approximately one hundred-fold superior in catalytic performance to the previously invented TAML analogs is provided having the formula (I) wherein Y1, Y2, Y3 and ...  
WO/2017/049096A1
The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, and/or a compound of 14 or 14*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to prov...  
WO/2017/049080A1
The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compounds 7, 7* and ...  
WO/2017/037596A1
The present application relates to amorphous solid dispersion of LCZ-696 with one or more pharmaceutically acceptable carrier. Specifically, the present application relates to amorphous solid dispersion of LCZ-696 with one or more pharma...  
WO/2017/001926A3
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the trea...  
WO/2017/037639A1
The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of ex...  
WO/2017/037591A1
The present invention relates to a process for preparing amorphous form of Sacubitril / Valsartan sodium salt of Formula-II and pharmaceutical composition comprising thereof.  
WO/2017/032728A1
The invention relates to substituted ketoxime benzoylamides of general formula (I) as herbicides. In said formula (I), R1', R2', X, Y and W represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen...  
WO/2017/020841A1
Disclosed is a pharmaceutical composition containing a specific crystalline powder of LCZ696. The crystalline powder of LCZ696 having a specific powdery feature satisfies a requirement of a preparation process and can be used to produce ...  
WO/2017/012917A1
Several methods for the preparation of an amorphous powder comprising a 1:1 stoichiometric mixture of the trisodium salts of Valsartan and Sacubitril are described, as well as the resulting amorphous powder, pharmaceutical compositions c...  
WO/2017/013265A1
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...  
WO/2017/009784A1
The present invention describes an amorphous form of trisodium salt of valsartan sacubitril complex and a process for the preparation of same comprising: reacting sacubitril sodium and valsartan disodium or sacubitril and valsartan in th...  
WO/2017/005567A1
The invention relates to N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives of the general formula (I) as herbicides. In said formula (I), V, X, and Z represent groups such as hydrogen, and organic groups such as alkyl...  
WO/2017/005585A1
The invention relates to a thermodynamically stable crystal modification of 2-chloro-3-(methylsulfanyl)-n-(1-methyl-1H-tetrazol-5-yl)-4- (trifluoromethyl)benzamide. This thermodynamically stable crystal modification has particular advant...  
WO/2017/007790A1
The present invention relates to compounds according to Formula (I) or Formula (II), which are potential bone imaging agents and therapeutic agents for treating bone tumors and metastases. Certain compounds labeled with 68Ga displayed ex...  
WO/2017/002120A1
Compounds useful for selectively eliminating senescent cells, compositions comprising same and uses thereof in treating diseases and disorders in which selective elimination of senescent cells is beneficial are provided. The compounds ar...  
WO/2016/210234A1
The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to composit...  
WO/2016/206101A1
The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.  
WO/2016/198374A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2016/201238A1
Solid state forms of trisodium vaisartan : sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.  
WO/2016/193190A1
The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.  
WO/2016/192099A1
The present invention takes a candesartan cyclic compound as a starting material and performs thereon a three-step reaction of adding tetrazole, hydrolysis and adding a protecting group to directly obtain trityl candesartan without separ...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/185200A1
The invention provides a compound which is a peptide derivative of formula (1) as defined in the claims or a salt thereof: RG is H, -CH2-RGA or C1-12 hydrocarbyl optionally substituted with 1 to 4 substituents selected from -OR', -NO2, -...  
WO/2016/187521A1
A pharmaceutical formulation includes an antibiotic 5-substituted 1H-tetrazole compound in an amount sufficient to treat a bacterial infection, the antibiotic 5-substituted 1H-tetrazole compound being selected from the group consisting o...  
WO/2016/176689A1
Tetrazine non-canonical amino acids, methods for genetic encoding proteins and polypeptides using the tetrazine amino acids, proteins and polypeptides comprising the tetrazine amino acids, and compositions comprising the proteins and pol...  
WO/2016/169902A1
The present invention relates to compounds of formula (I), wherein R1' is CH3 R1' is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1, and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethy...  
WO/2016/114634A3
The present invention relates to a cyclam derivative compound and a pharmaceutical use thereof. The cyclam derivative compound can alleviate side effects of a drug since the compound enables an efficient drug delivery by selectively reco...  
WO/2016/153054A1
Provided are an efficient method for producing a nitrogen-containing compound or salt thereof to be used in the production of a treatment agent for diseases involving an integrin. Also provided is a production intermediate of the same. A...  
WO/2015/143188A8
Provided herein are 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin -2- yl)-3-(1H-tetrazol-1-yl)propan-2-ols and processes for their preparation.  
WO/2016/150337A1
The present invention relates to a new crystal form of a compound of formula (I), a preparation method and a use thereof. The new crystal form provided in the present invention is stable and has a low hygroscopicity, and a purification p...  
WO/2016/146299A1
A process to isolate a compound of Formula (2a) or a salt or solvate thereof, comprising a) reacting a mixture of diastereoisomers of Formulae (2a, 2b) with a basic heterocyclic-aldehyde compound and an optically active amine in the pres...  
WO/2016/149486A1
The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for p...  
WO/2016/142364A1
The invention discloses a method for the preparation of certain 1,5 disubstituted tetrazole and similar compounds starting from certain thioacetamides, which ultimately allows the preparation of these certain 1,5 disubstituted tetrazoles...  
WO/2016/089208A3
The present invention is directed to compounds having formula (I): A-L-R1, wherein A is an anticancer agent comprising at least one group selected from the group comprising OH, NH and NH2 and L is a direct bond or L is a linker and R1 is...  
WO/2016/127873A1
The present invention provides an isothiocyanate compound and an application thereof. The compound is an aryl substituted isothiocyanate compound that has a structure in the general formula I. The isothiocyanate compound in the present i...  

Matches 201 - 250 out of 5,949